What are the challenges in commercial non-tuberculous mycobacteria (NTM) drug discovery and how should we move forward?
Expert Opin Drug Discov
; 15(1): 7-9, 2020 01.
Article
em En
| MEDLINE
| ID: mdl-31566439
Introduction: Despite the great clinical need, the development of drugs for treating non-tuberculous mycobacteria lung disease (NTM-LD), partly from the scientific difficulty, but also because the eventual size and types of markets for commercially-developed drugs has been unclear.Areas Covered: Here, key questions regarding the markets for commercial NTM-LD drugs are discussed, together with potential solutions for resolving these questions.Expert Opinion: Many of these questions will become better resoled over time, but uncertainties will remain around likely competition and whether approval and reimbursement will be achieved for all NTM-LD or smaller subsections of the market. Additionally, both 'push' and 'pull' incentives should be considered by policymakers to ensure the NTM-LD market is successfully addressed.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Descoberta de Drogas
/
Antibacterianos
/
Micobactérias não Tuberculosas
/
Infecções por Mycobacterium não Tuberculosas
Tipo de estudo:
Incidence_studies
/
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Opin Drug Discov
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Estados Unidos